chitosan and plga microspheres as drug delivery ... - UniCA Eprints
chitosan and plga microspheres as drug delivery ... - UniCA Eprints
chitosan and plga microspheres as drug delivery ... - UniCA Eprints
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
9. References113. Ezekiel D.H., Hutchins J.E. Mutations affecting RNAP <strong>as</strong>sociated with rifampicin resistancein Escherichia coli. Nature London. Vol. 220, p. 276-277, 1968.114. Wehrli W., Neusch J., Knusel F., Staehelin M. Action of rifamycin on RNA olymer<strong>as</strong>e fromsensitive <strong>and</strong> resistant bacteria. Biochem. Biophys. Res. Commun. Vol. 32, p. 284-288, 1968b.115. Heil A., <strong>and</strong> Zillig W. Reconstitution of bacterial DNA-dependent RNA polymer<strong>as</strong>e fromisolated subunits <strong>as</strong> a tool for the elucidation of the role of the subunits in transcription. FEBSLett. Vol. 11, p. 165-168, 1970.116. Ram<strong>as</strong>wamy S., <strong>and</strong> Musser J.M. Molecular genetic b<strong>as</strong>is of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. vol. 79, p. 3-29, 1998.117. Heep M., Rieger U., Beck D., <strong>and</strong> Lehn N. Mutations in the beginning of the rpoB gene caninduce resistance to rifamycins in both Helicobacter pylori <strong>and</strong> Mycobacterium tuberculosis.Antimicrob. Agents <strong>and</strong> Chemotherapeutics. Vol. 44, p. 1075-1077, 2000.118. Ovchinnikov Y.A., Mon<strong>as</strong>tyrskaya G.S., Guriev S.O., Kalinina N.F., Sverdlov E.D. Gragerov,A.I. B<strong>as</strong>s, I.A. Kiver, I.F. Moiseyeva, E.P. Igumnov, V.N. et al. RNA polymer<strong>as</strong>e rifampicinresistance mutations in Escherichia coli: sequence proved changes <strong>and</strong> dominance. Mol. Gen.Genet. Vol. 190, p. 344-348, 1983.119. Lisitsyn N.A., Gur’ev S.O., Sverdlov E.D., Moiseeva E.P., <strong>and</strong> Nikiforov V.G. Nucleotidesubstitutions in the rpoB gene leading to rifampicin resistance of E. coli RNA polymer<strong>as</strong>e. BioorgKhim. Vol. 10, p. 127-128, 1984a.120. Lisitsyn N.A., Sverdlov E.D., Moiseyeva E.P., Danilevskaya O.N., <strong>and</strong> Nikiforov V. Mutationto rifampicin resistance at the beginning of the RNA polymer<strong>as</strong>e beta subunit gene in Escherichiacoli. Mol. Gen. Genet. Vol. 196, p. 173-174, 1984b.121. Jin D.J., <strong>and</strong> Gross C.A. Mapping <strong>and</strong> sequencing of mutations in the Escherichia coli rpoBgene that lead to rifampicin resistance. J. Mol. Biol. Vol. 202, p. 45-58, 1988.122. Severinov K. Soushko, M. Goldfarb, A. <strong>and</strong> Nikiforov A. Rifampicin region revisited. Newrifampicin-resistant <strong>and</strong> streptoly-digin-resistant mutants in the beta subunit of Escherichia coliRNA polymer<strong>as</strong>e. J. Biol. Chem. Vol. 268, p. 14820-14825, 1993.123. Severinov K., Soushko M., Goldfarb A., <strong>and</strong> Nikiforov V. RifR mutations in the beginning ofthe Escherichia coli rpoB gene. Mol. Gen. Genet. Vol. 244, p. 120-126, 1994.124. Blomberg B., Evans, P. Phanouvong S., Nunn P. Informal consultation on 4-<strong>drug</strong> fixed dosecombinations (4FDCs) compliant with the WHO model list of essential <strong>drug</strong>s. World HealthOrganization, Geneva, WHO/CDS/TB/2002. vol. 299, p. 15-17, 2002.125. Grant D.J.W. Theory <strong>and</strong> origin of polymorphism. In: Brittain, H.G. (Ed.), Polymorphism inPharmaceutical Solids. Marcel Dekker, New York. p. 1-34, 1999.126. Pelizza G., Nebuloni M., Ferrari P., Gallo G.G. Polymorphism of rifampicin. Il Farmaco. Vol.32, p. 471-481, 1977.127. Henwood S.Q., Liebenberg W., Tiedt L.R., Lotter A.P., Villers M.M. Characterization of thesolubility <strong>and</strong> dissolution properties of several new rifampicin polymorphs, solvates <strong>and</strong> hydrates.Drug Dev. Ind. Pharm. Vol. 27, p. 1017-1030, 2001.128. Mathiowitz E., Langer R. Polyanhydride <strong>microspheres</strong> <strong>as</strong> <strong>drug</strong> carriers I. Hot meltmicroencapsulation. J. Control. Rel. vol. 5, p. 13-22, 1987.129. Folkman J., Long D.M. The use of silicone rubber <strong>as</strong> a carrier for prolonged <strong>drug</strong> therapy. J.Surg. Res. Vol. 4, p. 139-142, 1964.130. Desai S.J., Siminelli A.P., Higuchi W.I. Investigation of factors influencing rele<strong>as</strong>e of solid<strong>drug</strong> dispersed in inert matrixes. J. Pharm. Sci. vol. 54, p. 1459-1464, 1965.131. Jalil R., Nixon J.R. Biodegradable poly(lactic acid) <strong>and</strong> poly(lactide-co-glycocide)microcapsules: problems <strong>as</strong>sociated with preparative techniques <strong>and</strong> rele<strong>as</strong>e properties. J.Microencapsul. Vol. 7, p. 297-325, 1990b.132. Chang T.M.S. Semipermeable microcapsules. Science. Vol. 146, p. 524-525, 1964.133. M<strong>as</strong>on N., Thies C., Cicero T.J. In-vivo <strong>and</strong> in vitro evaluation of a microencapsulatednarcotic anagonist. J. Pharm. Sci. vol. 65, p. 847-850, 1976.134. Jain R.A. The manufacturing techniques of various <strong>drug</strong> loaded biodegradable poly(lactidecoglycolide)(PLGA) devices. Biomaterials.vol. 21, p. 2475-2490, 2000.127
Change language